8)     6 to <12 1,475 (2) 815 58 51 (3.5) 0.706 (0.497–1.003) 0.052 12 to <18 1,371 (1) 645 43 41 (3.0) 0.609 (0.413–0.899) 0.013 18 to <24 1,271 (2) 606 36 34 (2.7) 0.547 (0.361–0.828) 0.004 24 to <30 1,109 (4) 387 20 18 (1.6) 0.331 (0.197–0.559) <0.001 30 to <36 991 (0) 327 15 13 (1.3) 0.265 (0.147–0.478) <0.001 Total 1,581

(5)   258 208 (13.2)     N = number of patients included in the observation aAs some patients experienced a fracture in more check details than one time interval, the total was not the sum of patients with a fracture in each interval bAdjusted model by age, prior bisphosphonate use and a history of fracture in the last 12 months before MG-132 cost starting teriparatide cCompared with 0 to <6 months interval Figure 2 presents the adjusted odds of fracture (95% confidence interval [CI]) by fracture type for each 6-month interval in the total study cohort (adjusted by age, prior bisphosphonate use and history

find more of fracture in the 12 months before starting teriparatide). For all fractures and for vertebral fractures, there was a significant reduction in the adjusted odds of fracture at 12 to <18 months of teriparatide treatment and during the post-teriparatide intervals compared with the first 6 months of teriparatide treatment. For all fractures, there was a 74% decrease in the adjusted odds of fracture in the 30- to <36-month period compared with 0 to <6 months (p < 0.001). The odds of having

a non-vertebral fracture were significantly lower during the 24- to <30-month interval (OR 0.40, 95% CI 0.21 to 0.75) and 30- to <36-month interval (OR 0.41, 95% CI 0.22 to 0.76), compared with the first 6 months of teriparatide treatment. Similar results were observed for the main non-vertebral Methane monooxygenase fractures. Fig. 2 Adjusted odds of fracture (95% CI) by fracture type (all fractures pooled, clinical vertebral, non-vertebral and main non-vertebral) in each 6-month interval for the total study cohort. Note: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 versus 0 to <6 months; model: log(OddsofFracture) = 6 month interval + age + prior bisphosphonate use + fracture in last 12 months. Models adjusted by age, prior bisphosphonate use and a history of fracture in the last 12 months before starting teriparatide. Main non-vertebral fractures includes forearm/wrist, hip, humerus, leg and ribs After adjusting for the other relevant risk factors, patients who had a fracture in the 12 months before baseline were more likely to fracture during the study than patients without a fracture in the 12 months before baseline (119 [15.6%] of 761 patients and 89 [10.9%] of 815 patients, respectively, experienced a fracture during the study): adjusted OR 1.39 (95% CI 1.05–1.83). In addition, patients who used bisphosphonates prior to teriparatide were more likely to fracture during the study than those without prior bisphosphonate use (169 [14.